Abstract: Methods and systems integrate direct carbon capture and desalination processes to various degrees, benefiting from synergies in the combined processes. A method includes receiving an input liquid comprising a brine reject stream from a water treatment facility and pre-treating the input liquid. The pre-treatment includes one or more of filtration, a reverse osmosis, and ion exchange. The method also includes performing an electrochemical process on the input liquid to produce at least one hydroxide-rich stream and capturing CO2 from air using the hydroxide-rich stream and a passive air capture system, thereby producing a liquid carbonate solution containing air-captured CO2. In some cases byproducts and recovered water can be used by the water treatment facility and/or the carbon capture process.

Abstract: The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration. The present disclosure further provides powder compositions for reconstitution to provide a liquid formulation. In further aspects, the present disclosure relates to processes for preparation of such pharmaceutical compositions, and methods of treating a subject in need of losartan by administration of a formulation described herein.

Abstract: According to various aspects of this disclosure, the present disclosure relates to long-acting, shelf-stable microsphere formulations of bupivacaine, kits, and methods for treating or preventing pain by parenteral injection of a microsphere formulation of bupivacaine.

Abstract: The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration. The present disclosure further provides powder compositions for reconstitution to provide a liquid formulation. In further aspects, the present disclosure relates to processes for preparation of such pharmaceutical compositions, and methods of treating a subject in need of losartan by administration of a formulation described herein.

Abstract: The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration. The present disclosure further provides powder compositions for reconstitution to provide a liquid formulation. In further aspects, the present disclosure relates to processes for preparation of such pharmaceutical compositions, and methods of treating a subject in need of losartan by administration of a formulation described herein.

Abstract: A method for capturing and sequestering carbon dioxide (CO2) includes receiving and performing an electrochemical process on the input liquid including water and a salt to produce at least one hydroxide-rich stream, and then capturing CO2 from air using the hydroxide-rich stream and a passive air capture system, thereby producing a liquid carbonate solution containing air-captured CO2. Optional steps include disposing of the liquid carbonate solution, precipitating air-captured CO2 from the liquid carbonate solution as solid carbonate and/or a slurry of carbonate, and mixing the liquid carbonate solution with a hydrogen-rich stream produced by the electrochemical process to generate gaseous CO2. Various integrations and synergies among CO2 capture, renewable energy, water desalination, and metal and mineral extraction are provided.

Abstract: The present disclosure is directed to formulations, devices, kits, and methods for treating or preventing motor symptoms associated with Parkinson's disease by injection of a microsphere formulation of apomorphine free base or a pharmaceutically acceptable a salt thereof, wherein injection can be from a pre-filled injector.

Abstract: The present disclosure is directed to formulations and methods for treating or preventing head pain, including migraines, with dihydroergotamine mesylate.

Abstract: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.

Abstract: Described herein are micronized powder particles of colistimethate sodium wherein at least 50% by volume of the micronized particles have a diameter of less than 7 micrometers but not less than 3 micrometers and the powder has a total moisture content of from 5 to 10% by weight, for use in the treatment of a pulmonary infection by powder inhalation, wherein the colistimethate sodium is not separated into component form. The micronized powder particles of colistimethate sodium are useful in the treatment of infections caused by gram-negative bacteria, particularly in patients suffering from cystic fibrosis.

Abstract: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.

Abstract: The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.

Abstract: Described herein are micronized powder particles of colistimethate sodium wherein at least 50% by volume of the micronized particles have a diameter of less than 7 micrometres but not less than 3 micrometres and the powder has a total moisture content of from 5 to 10% by weight, for use in the treatment of a pulmonary infection by powder inhalation, wherein the colistimethate sodium is not separated into component form. The micronized powder particles of colistimethate sodium are useful in the treatment of infections caused by gram-negative bacteria, particularly in patients suffering from cystic fibrosis.

Abstract: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.

Abstract: The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.

Abstract: The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.

Abstract: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.

Abstract: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.

Abstract: The present invention relates to crystalline forms of linaclotide, as well as to various methods and processes for the preparation and use of the crystalline forms.

Abstract: The present invention relates to crystalline forms of linaclotide, as well as to various methods and processes for the preparation and use of the crystalline forms.